Table 2 Targetable ctDNA alterations found in 44 of the 119 NSCLC patients by NGS-based assay.

From: Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

Gene

Alterations

n

Targeted agents

EGFR

p.G719A

2

EGFR-TKIs

EGFR

p.I740_K745dup, p.E746_A750del, p.E746_T751delinsI

8

EGFR-TKIs

EGFR

p.S768I

1

EGFR-TKIs

EGFR

p.L858R

5

EGFR-TKIs

EGFR

p.S768I + p.H835L

1

EGFR-TKIs

EGFR

p.L833V + p.L858R

1

EGFR-TKIs

EGFR

p.A767_V769dup

1

Resistant to EGFR-TKIs

FBXW7

p.R505H

mTOR inhibitors

EGFR

p.E746_P753delinsVS

1

Resistant to EGFR-TKIs

BRAF

p.V600E

 

Vemurafenib

EGFR

p.E746_A750del

1

EGFR-TKIs

FBXW7

p.R505S

mTOR inhibitors

EGFR

p.E746_A750del

1

EGFR-TKIs

NF1

p.S1030Ifs*8

mTOR inhibitors

TP53

p.P80Gfs*65

APR-246, MK-1775

EGFR

p.L858R

1

Resistant to EGFR-TKIs

NRAS

p.Q61K

MEK inhibitors

EGFR

p.L858R

1

EGFR-TKIs

PIK3CA

p.H1047R

mTOR inhibitors

EGFR

p.L858R

1

EGFR-TKIs

TP53

p.R342*

APR-246, MK-1775

ALK

EML4-ALK

1

Crizotinib

MET

p.Y1248H

1

Crizotinib

RET

KIF5B-RET

1

Cabozantinib

BRAF

p.V600E, p.G469V

2

Vemurafenib

BRAF

p.G469A

1

Vemurafenib

TP53

p.C141*

APR-246, MK-1775

BRAF

p.N581S

1

Vemurafenib

ATM

p.E2449*

1

PARP inhibitors

FBXW7

p.R505H, p.R505H + p.R465H

2

mTOR inhibitors

FBXW7

p.R505H

1

mTOR inhibitors

PIK3CA

p.M1043I

 

KRAS

p.G12C, p.G12D

4

MEK inhibitors

NF2

p.Q111*

1

mTOR inhibitors

TP53

p.S183*

APR-246, MK-1775

PTEN

p.R130*

1

mTOR inhibitors

STK11

p.Y60Lfs*103

1

mTOR inhibitors

TP53

p.N239Ifs*7

1

APR-246, MK-1775

Back to article page